

CITATION REPORT

List of articles citing

Clinical implications of c-Kit mutations in acute myelogenous leukemia

DOI: 10.1007/s11899-009-0011-8

Current Hematologic Malignancy Reports, 2009, 4, 77-82.

Source: <https://exaly.com/paper-pdf/46218431/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
65	Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity. <i>Biochemical Journal</i> , 2011 , 438, 155-64	3.8	7
64	High-resolution kinetics of cytokine signaling in human CD34/CD117-positive cells in unfractionated bone marrow. <i>Blood</i> , 2011 , 117, e131-41	2.2	18
63	PTPIP51 is phosphorylated by Lyn and c-Src kinases lacking dephosphorylation by PTP1B in acute myeloid leukemia. <i>Leukemia Research</i> , 2011 , 35, 1367-75	2.7	13
62	The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2012 , 2, e81	7	11
61	Expression of c-Kit and PDGFR α in epithelial ovarian tumors and tumor stroma. <i>Oncology Letters</i> , 2012 , 3, 369-372	2.6	9
60	Immunophenotyping. 72-112		1
59	KIT mutation detection in Tunisian patients with newly diagnosed myelogenous leukemia: prevalence and prognostic significance. <i>Cancer Genetics</i> , 2012 , 205, 436-41	2.3	3
58	New agents for acute myeloid leukemia: is it time for targeted therapies?. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 179-89	5.9	15
57	Activating Mutations and Targeted Therapy in Cancer. 2012 ,		3
56	The detection of KIT mutations in acute myeloid leukemia. <i>Einstein (Sao Paulo, Brazil)</i> , 2012 , 10, 286-91	1.2	1
55	Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. <i>Journal of Cellular Biochemistry</i> , 2012 , 113, 1314-22	4.7	57
54	Blastic leukaemias (AML): a biologist's view. <i>Cell Biochemistry and Biophysics</i> , 2013 , 66, 13-22	3.2	19
53	Redox control of leukemia: from molecular mechanisms to therapeutic opportunities. <i>Antioxidants and Redox Signaling</i> , 2013 , 18, 1349-83	8.4	96
52	Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. <i>Blood</i> , 2013 , 121, 2064-73	2.2	82
51	A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth. <i>Cancer Biology and Therapy</i> , 2014 , 15, 1208-18	4.6	9
50	Beyond H&E: integration of nucleic acid-based analyses into diagnostic pathology. <i>Veterinary Pathology</i> , 2014 , 51, 238-56	2.8	22
49	Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression. <i>Experimental Hematology</i> , 2014 , 42, 90-100	3.1	8

48	Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. <i>Immunology and Allergy Clinics of North America</i> , 2014 , 34, 219-37	3.3	53
47	Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia. <i>Archives of Medical Research</i> , 2014 , 45, 343-50	6.6	27
46	GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. <i>Leukemia</i> , 2014 , 28, 1252-1258	10.7	38
45	Cluster of differentiation 96 as a leukemia stem cell-specific marker and a factor for prognosis evaluation in leukemia. <i>Molecular and Clinical Oncology</i> , 2015 , 3, 833-838	1.6	14
44	Kit transduced signals counteract erythroid maturation by MAPK-dependent modulation of erythropoietin signaling and apoptosis induction in mouse fetal liver. <i>Cell Death and Differentiation</i> , 2015 , 22, 790-800	12.7	10
43	Key molecular mechanisms associated with cell malignant transformation in acute myeloid leukemia. <i>Molecular Biology</i> , 2016 , 50, 344-352	1.2	2
42	AML multi-gene panel testing: A review and comparison of two gene panels. <i>Pathology Research and Practice</i> , 2016 , 212, 372-80	3.4	3
41	The spleen microenvironment influences disease transformation in a mouse model of KIT-dependent myeloproliferative neoplasm. <i>Scientific Reports</i> , 2017 , 7, 41427	4.9	3
40	Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 343-355	5.9	16
39	Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017 , 10, 1-7	2.7	36
38	Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges. <i>Current Pharmaceutical Design</i> , 2017 , 23, 4303-4310	3.3	4
37	Predictive Markers and Driver Genes From Treatment Trials: Potential Utility For Early Diagnosis. 2017 , 231-244		
36	Polycomb Group Protein YY1 Is an Essential Regulator of Hematopoietic Stem Cell Quiescence. <i>Cell Reports</i> , 2018 , 22, 1545-1559	10.6	25
35	The Importance of the Right Framework: Mitogen-Activated Protein Kinase Pathway and the Scaffolding Protein PTPIP51. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	5
34	Cellular and viral oncogenes: the key to unlocking unknowns of Kaposi's sarcoma-associated herpesvirus pathogenesis. <i>Archives of Virology</i> , 2018 , 163, 2633-2643	2.6	7
33	Detection of KIT mutations in core binding factor acute myeloid leukemia. <i>Leukemia Research Reports</i> , 2018 , 10, 20-25	0.6	7
32	Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia. <i>Oncogenesis</i> , 2019 , 8, 39	6.6	17
31	Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	21

30	From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?. <i>Blood Reviews</i> , 2019 , 37, 100587	11.1	13
29	Potential CD34 signaling through phosphorylated-BAD in chemotherapy-resistant acute myeloid leukemia. <i>Journal of Receptor and Signal Transduction Research</i> , 2019 , 39, 276-282	2.6	2
28	Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. <i>Cancer Cell</i> , 2019 , 35, 738-751.e9	24.3	93
27	Specific Detection of c-Kit Expressed on Human Cell Surface by Immunosensor Based on Surface Plasmon Resonance. <i>Analytical Sciences</i> , 2019 , 35, 223-225	1.7	2
26	Persistent Human KIT Receptor Signaling Disposes Murine Placenta to Premature Differentiation Resulting in Severely Disrupted Placental Structure and Functionality. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	1
25	Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 288	21	27
24	Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. <i>Frontiers in Oncology</i> , 2020 , 10, 612880	5.3	24
23	Driver mutations in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2020 , 27, 49-57	3.3	16
22	Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 2968-2980	5.6	9
21	The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021 , 11,	5.4	2
20	Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. <i>ESMO Open</i> , 2021 , 6, 100040	6	7
19	Tumor suppressors in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2320-2330	1.9	2
18	A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1876, 188631	11.2	4
17	[The significance of C-KIT gene mutations in the diagnosis and prognosis of malignant tumors]. <i>Arkhiv Patologii</i> , 2021 , 83, 61-68	0.2	
16	Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia. <i>Cancers</i> , 2021 , 13,	6.6	10
15	Correlation between important genes of mTOR pathway (and) in Iranian women with sporadic breast cancer. <i>Medical Journal of the Islamic Republic of Iran</i> , 2018 , 32, 135	1.1	5
14	A concise review on the molecular genetics of acute myeloid leukemia. <i>Leukemia Research</i> , 2021 , 111, 106727	2.7	4
13	Signal Transduction Inhibitors of the HER Family. 2013 , 35-68		

12	Role of CD135/CD117 on Prognosis and Overall Survival of Acute Myeloid Leukemia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019 , 20, 2625-2631	1.7	0
11	The Relationship between Copy Number Variation, Protein Expression, and Angiogenesis in Sporadic Breast Cancer. <i>Reports of Biochemistry and Molecular Biology</i> , 2020 , 9, 40-49	1.3	2
10	The Relation between Exon Variations of KIT Gene and Clinical Pathological Factors of Breast Cancer. 2020 , 5, 137-148		2
9	A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients.. <i>Frontiers in Oncology</i> , 2021 , 11, 783114	5.3	
8	Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	2
7	The Importance of RTK Signaling Genes and their Inhibitors in Breast Cancer. <i>Journal of Obstetrics, Gynecology and Cancer Research</i> , 2022 , 7, 258-271		
6	Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives. 2022 , 100996		0
5	Precision Medicine in Myeloid Malignancies: Hype or Hope?.		1
4	Does Generic Cyclic Kinase Insert Domain of Receptor Tyrosine Kinase KIT Clone Its Native Homologue?. 2022 , 23, 12898		0
3	Patterns of use of biological and genetic markers for chronic lymphocytic leukemia and acute myeloid leukemia in Puerto Rico.		0
2	Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. 2022 , 10, 3008		0
1	Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine. 2023 , 22, 100517		0